A curated record of project, technology, standards and collaboration milestones that continue to demonstrate AM Technologies by Brinter's capabilities. Selected event participation is retained as part of the company record without unnecessary legacy links.
A new peer-reviewed study used Brinter Core during a parabolic-flight campaign as a representative prototype for the ESA 3D-BioSystem concept, demonstrating extrusion bioprinting in microgravity and validating a cryopreservation-based bioink supply-chain strategy for future crewed space missions.
AM Technologies by Brinter will participate in HealthBIO in Turku, Finland, on 2–3 September 2026, meeting companies, researchers, investors and other stakeholders across the health and life-science ecosystem.
AM Technologies by Brinter is participating in the BioCity Symposium in Turku, Finland, on 27–28 August 2026, connecting with researchers, clinicians and industry across life sciences, biotechnology and healthcare.
2026 research connected rheology, extrusion pressure, wall shear stress, nozzle geometry and computational optimisation, strengthening the path from empirical parameter tuning toward predictive additive manufacturing process design.
Brinter AM Technologies joined the Finnish Additive Manufacturing Ecosystem (FAME), strengthening collaboration across Finland's additive manufacturing value chain and supporting international visibility for Finnish AM capabilities.
Brinter AM Technologies participates in the steering group of the four-year CirBReS consortium, connecting sustainable bio-based material development with industrial additive manufacturing and future manufacturing routes.
AM Technologies by Brinter will participate in the 35th Annual Conference of the European Society for Biomaterials in Antwerp, showcasing our advanced additive manufacturing technologies through the STRONG-UR and KeratOPrinter projects and demonstrating how modular manufacturing platforms can support next-generation regenerative medicine applications.
HTWK Leipzig installed a Brinter AM Technologies research platform capable of combining four materials and four processes in each layer, with independent cooling, heating, mixing and UV crosslinking capabilities.
AM Technologies by Brinter participated in the CEN/CENELEC and JRC standardization community discussion around equipment design, process traceability, data interoperability and reproducibility in biomanufacturing.
Manufacturing technology development for corneal regeneration using advanced additive manufacturing and laser-assisted bioprinting.
Participation in a long-term additive manufacturing ecosystem focused on translating advanced materials and manufacturing technologies toward life-science applications.
Development of granulate-based additive manufacturing, foamed thermoplastic processing and digitally controlled manufacturing for more sustainable polymer value chains.
An open-source framework extending 3MF for bioprinting data, material metadata, interoperability, traceability and regulatory-aware manufacturing workflows.
2025 research advanced Brinter-enabled semi-solid extrusion from personalised dosage forms toward dual-release tablets and long-term controlled drug-delivery systems in which geometry, material formulation and post-processing define release behaviour.
A modular manufacturing platform adapted for patient-specific tubular regenerative structures and controlled multi-material biofabrication.
Development around lower-energy photochemistry and red-light crosslinking for material systems where conventional UV exposure is not ideal. Later peer-reviewed work demonstrated traceless 625 nm red-light photopolymerization of cell-laden GelMA structures.
Combining reproducible bioinks, progressive-cavity extrusion and Brinter platforms to improve standardization, process consistency and cross-system repeatability.
A Green Chemistry study used Brinter ONE to print photocurable living materials containing cyanobacteria and microalgae for light-driven biocatalytic chemical-production research, extending the platform beyond conventional tissue-engineering applications.
AM Technologies by Brinter worked with Redwire Space NV under an ESA programme to adapt Brinter Core technology to the demanding technical and operational requirements of an ISS-class microgravity research environment. Related microgravity development also included Brinter participation in the 3DSkinSpace parabolic-flight campaign with TU Dresden and ETH Zurich.
2023 research connected Brinter-associated extrusion workflows with tissue-adhesive, antioxidant and protein-delivery biomaterial systems, showing additive manufacturing as a route to engineered biological function rather than geometry alone.
Research across 2022–2026 used Brinter direct-ink-writing and extrusion technology for soft pressure sensors, organic electrochemical transistors and conductive hydrogel biosensing interfaces, showing the platform's reach into functional electronics and soft bioelectronics.
Peer-reviewed studies used Brinter 1 and the Pneuma Tool to manufacture tailored veterinary medicines by semi-solid extrusion, demonstrating an early pharmaprinting workflow for accurate small-batch and point-of-care production.
A progressive-cavity extrusion module designed for precise dispensing, low dead volume and improved repeatability across demanding biomaterial workflows.
Blue-light based chamber disinfection integrated into the modular bioprinting environment to support cleaner and more controlled manufacturing workflows.
Brinter presented its role in the Horizon 2020 RESTORE project, including new printing modalities, bioink optimisation and printing-protocol development for personalised cartilage regeneration.
A VTT study documented granule-fed additive manufacturing of renewable thermoplastic cellulose composites, providing an early research proof point for Brinter's broader material-extrusion technology foundation.
Early RESTORE trials used nanocellulose/alginate bioink with the Brinter platform and mechanically driven Visco Tool, documenting printability, line width and dimensional stability before later cell-viability work.
The archive prioritises developments that continue to demonstrate technology depth, engineering capability, collaboration, standardization or progress toward reliable manufacturing. Past event entries may remain as a record even when their original promotional link is no longer useful.